These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9352577)

  • 1. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County.
    London SJ; Sullivan-Klose T; Daly AK; Idle JR
    Pharmacogenetics; 1997 Oct; 7(5):401-4. PubMed ID: 9352577
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
    London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
    Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic analysis of CYP2C9 polymorphism in a Japanese population.
    Nasu K; Kubota T; Ishizaki T
    Pharmacogenetics; 1997 Oct; 7(5):405-9. PubMed ID: 9352578
    [No Abstract]   [Full Text] [Related]  

  • 4. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.
    Goldstein JA
    Br J Clin Pharmacol; 2002 Apr; 53(4):409-10. PubMed ID: 11966681
    [No Abstract]   [Full Text] [Related]  

  • 5. CYP2C9 polymorphism and warfarin dose requirements.
    Daly AK; Day CP; Aithal GP
    Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
    [No Abstract]   [Full Text] [Related]  

  • 6. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Rodriguez-Lescure A; Agúndez JA
    Cancer Lett; 2002 Jun; 180(1):41-6. PubMed ID: 11911968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin dose requirement and CYP2C9 polymorphisms.
    Halkin H; Lubetsky A
    Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
    Miners J
    Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
    Borlak J; Thum T
    Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
    [No Abstract]   [Full Text] [Related]  

  • 12. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
    Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
    Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk.
    Yasar U; Eliasson E; Dahl ML
    Carcinogenesis; 2002 Apr; 23(4):665; author reply 667-8. PubMed ID: 11960920
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
    Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
    Br J Clin Pharmacol; 2001 Oct; 52(4):447-50. PubMed ID: 11678789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
    Lee CR; Goldstein JA; Pieper JA
    Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutations of the CYP2C9 gene and the response to warfarin.
    Yasar U; Oscarson M; Eliasson E; Sjöqvist F
    Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472
    [No Abstract]   [Full Text] [Related]  

  • 18. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian.
    Inoue K; Yamazaki H; Shimada T
    Xenobiotica; 1998 Apr; 28(4):403-11. PubMed ID: 9604303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
    Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
    J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population.
    Zarza J; Hermida J; Montes R; Alberca I; López ML; Rocha E
    Blood; 2002 Jul; 100(2):734. PubMed ID: 12123234
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.